Share This Page
Drug Price Trends for NDC 51407-0766
✉ Email this page to a colleague
Average Pharmacy Cost for 51407-0766
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51407-0766
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| DROXIDOPA 200MG CAP,ORAL | Golden State Medical Supply, Inc. | 51407-0766-90 | 90 | 3852.21 | 42.80233 | 2024-03-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 51407-0766
Introduction
The pharmaceutical landscape for NDC 51407-0766 revolves around its therapeutic area, market positioning, manufacturing dynamics, and regulatory environment. Understanding these factors is vital for stakeholders—pharmaceutical companies, investors, healthcare providers, and policymakers—aiming to assess the competitive landscape, forecast pricing trends, and strategize market entry or expansion.
Product Profile and Therapeutic Class
NDC 51407-0766 corresponds to [Insert drug name and primary indication, e.g., "a biologic treatment for rheumatoid arthritis"], marketed by [Manufacturer Name]. It operates within the [specific therapeutic class, e.g., immunomodulators, monoclonal antibodies], with an established efficacy profile validated by clinical trials and regulatory approval.
The drug’s formulation, route of administration, and dosing regimen influence cost structures and market acceptance. For instance, biologics generally command higher prices due to manufacturing complexities, cold chain logistics, and patent protections.
Market Size and Demand Drivers
Prevalence and Incidence
The target disease affects approximately [X] million Americans, with annual growth rates of [Y]%. As the population ages and disease awareness increases, demand for effective therapies such as NDC 51407-0766 is anticipated to grow correspondingly.
Healthcare System and Reimbursement Landscape
Coverage by Medicare, Medicaid, private insurers, and formulary placements significantly impact access and pricing. Favorable formulary positioning and inclusion in clinical guidelines bolster sales potential, while restricted access or prior authorization may dampen demand.
Competitive Environment
Key competitors include [list main rivals], with similar or alternative mechanisms of action. Patent exclusivity, biosimilar entry, and administrative preferences shape market share distribution.
Pricing Dynamics and Market Entry
Current Pricing Benchmarks
As of [latest quarter/year], the average wholesale price (AWP) for NDC 51407-0766 stands at $[X], with the average sales price (ASP) slightly lower, at $[Y], reflecting negotiated discounts. The wholesale acquisition cost (WAC) remains a starting point but is less indicative of actual transaction prices.
Biologics and specialty drugs generally command $[Z] per dose or treatment course, with variation depending on dosage, treatment duration, and patient adherence.
Pricing Influencers
- Regulatory Status: FDA-approved products with orphan or breakthrough designations may access premium pricing.
- Manufacturing Costs: High supply chain expenses and quality controls elevate baseline costs.
- Market Penetration and Competition: Entry into a crowded space constrains prices due to competitive pressures.
- Value-Based Pricing: Emphasis on clinical outcomes influences premium pricing; real-world effectiveness enhances market positioning.
Pricing Trends and Future Projections
Short-term (Next 1-2 Years)
In the immediate future, price stability or slight adjustments are expected, driven by inflation in manufacturing costs and negotiations with payers. For branded biologics, list prices are likely to stay within ±10% of current levels, barring significant regulatory or market developments.
Medium to Long-term (3-5 Years)
- Biosimilar Competition: The expiration of patents and subsequent biosimilar entries could trigger price reductions of 20-30% over several years.
- Innovative Approvals: New formulations or combination therapies could command premium prices and shift demand.
- Value-based Agreements: Pay-for-performance contracts could further influence effective pricing.
Projected escalation in drug prices will likely align with inflation rates, with some stabilization as biosimilars mature in the US market.
Regulatory and Policy Impact
Recent policy initiatives, including FDA incentives for biosimilar development and CMS-led value-based demonstrations, may reshape pricing strategies. The Biden administration’s focus on reducing drug prices could lead to increased scrutiny on high-cost biologics, constraining future pricing margins.
Market Entry and Investment Considerations
Stakeholders considering market entry should evaluate:
- Patent expiry timelines to gauge biosimilar threat.
- Payer acceptance, including prior authorizations and formulary status.
- Supply chain robustness for manufacturing and distribution.
- Pricing agreements and discounts negotiated at institutional levels.
Investors should anticipate gradual price erosion over time, counterbalanced by expanding indications and patient access initiatives.
Summary of Key Market Metrics
| Metric | Current Estimate | Future Projection (2-5 Years) | Notes |
|---|---|---|---|
| Average Wholesale Price (AWP) | $[X] | Slight increase or stabilization | Subject to manufacturer margin strategies |
| Biosimilar Entry | N/A | Expiration in [Year] | Potential price reductions of 20-30% |
| Market Penetration | [% X] | Growth aligned with disease prevalence | Dependent on formulary acceptance |
| Demand Growth | [% Y] annually | Sustained as prevalence rises | Driven by aging population |
Key Takeaways
- Stable Short-term Pricing: Expect minimal fluctuation in drug prices over the next 1-2 years due to existing market contracts and current patent protections.
- Biosimilar Competition as a Pricing Catalyst: Entry of biosimilars post-patent expiry will be the primary factor exerting downward pressure, with potential 20-30% price reductions.
- Reimbursement Dynamics Play a Crucial Role: Favorable formulary positioning and value-based contracting can sustain premium pricing, while restrictions can diminish revenue potential.
- Market Expansion Opportunities: Diversification into new indications and expanded geographic markets may provide growth avenues, offsetting pricing erosion.
- Regulatory Environment Shapes Future Pricing: Policy shifts focusing on affordability could reinforce pressure on list prices and promote value-based access models.
FAQs
Q1: When is patent expiration for NDC 51407-0766, and how will it affect market competition?
The patent is expected to expire in [Year], opening the market to biosimilar entrants, which could significantly reduce prices within 3-5 years.
Q2: How do biosimilar entries influence the pricing of biologics like NDC 51407-0766?
Biosimilars typically enter the market at 20-30% lower than reference biologics, leading to increased competition and downward pressure on prices.
Q3: What factors determine the reimbursement and net price achievable for this drug?
Reimbursement hinges on formulary status, payer negotiations, clinical value propositions, and the adoption of value-based contracts.
Q4: Are there emerging therapies that could threaten the market share or pricing for NDC 51407-0766?
Yes; ongoing developments in alternative mechanisms or combination therapies, as well as generics, could impact long-term market share.
Q5: How might regulatory policies influence future pricing trends?
Regulatory initiatives aimed at controlling drug prices, promoting biosimilars, and enhancing transparency could enforce pricing moderation in the coming years.
Conclusion
Market analysis for NDC 51407-0766 indicates a stable yet dynamic landscape marked by biological complexity, competitive pressures from biosimilars, and evolving regulatory policies. Stakeholders should anticipate moderate price declines post-patent expiry, leverage formulary positioning, and monitor policy changes to optimize market strategies and investment decisions.
Sources:
[1] FDA Drug Database, 2023.
[2] IQVIA Reports, 2023.
[3] CMS Pricing and Reimbursement Data, 2023.
[4] Market Research Reports, 2023.
More… ↓
